Will Arcadia Bio (NASDAQ:RKDA) continue to slip in April?

While some millenniums are indifferent towards basic materials space, it makes sense to go over Arcadia Bio in terms of its current potentials. As we have suggested previously, Arcadia Bio is beginning its slip as investors shift to be more bearish due to the increased sector volatility. Arcadia Bio barely shadows the market. The returns on investing in Arcadia Bio and the market returns of the last few months appear uncorrelated. Strong fundamental indicators of the company may suggest signs of short-term price drift for investors. Arcadia Bio is scheduled to announce its earnings today. The next earnings report is expected on the 12th of May 2021.
Published over a year ago
View all stories for Arcadia Biosciences | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

This firm's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Arcadia Bio market sentiment investors' perception of the future value of Arcadia. Let us look at a few aspects of Arcadia technical analysis. About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Arcadia Bio was at this time reported as 1.04. The company recorded a loss per share of 2.12. Arcadia Bio had not issued any dividends in recent years. The entity had a split on the 24th of January 2018.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Arcadia Biosciences. In general, sophisticated investors focus on analyzing Arcadia Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Arcadia Biosciences's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Arcadia Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Arcadia Biosciences, many experienced traders also check how macroeconomic factors affect Arcadia Biosciences price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcadia Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Arcadia Biosciences. Your research has to be compared to or analyzed against Arcadia Biosciences' peers to derive any actionable benefits. When done correctly, Arcadia Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Arcadia Biosciences.

How does Arcadia Stands against Peers?

Analyzing Arcadia Biosciences competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Arcadia Biosciences across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out Arcadia Biosciences Competition Details

Arcadia Biosciences Gross Profit

Arcadia Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Arcadia Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Arcadia Biosciences Gross Profit growth over the last 10 years. Please check Arcadia Biosciences' gross profit and other fundamental indicators for more details.

Closer look at Arcadia Bio Standard Deviation

Arcadia Bio has current Standard Deviation of 8.91. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.
Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.
Standard Deviation 
=  
SQRT(V) 
 = 
8.91
SQRT = Square root notation
V =   Variance of Arcadia Bio returns
Let's now compare Arcadia Bio Standard Deviation to its closest peers:
RKDA
NTR
FMC
YARIY
SMG
RKDA8.905086923691453
NTR1.84
FMC1.93
YARIY1.64
SMG2.37

Chances of Arcadia Bio investors to go out of control

Current Sortino Ratio is up to 0.01. Price may slip again. Arcadia Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Arcadia Bio independently to ensure intended market timing strategies are aligned with expectations about Arcadia Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arcadia Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arcadia Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Current Takeaway on Arcadia Bio Investment

Whereas other companies under the agricultural inputs industry are still a bit expensive, Arcadia Bio may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Arcadia Bio.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Arcadia Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com